On Nov. 13, 2017, the Department of Transportation (DOT) published a final rule that, among other items, expands DOT’s current drug testing panel to include certain semi-synthetic opioids (i.e., hydrocodone, oxycodone, hydromorphone, oxymorphone). Testing for methylenedioxyethylamphetamine (MDEA) has been removed while methylenedioxyamphetamine (MDA) has been added as an initial test analyte.
The final rule also clarifies existing drug testing program provisions and definitions, makes technical amendments and removes the requirement for employers and Consortium/Third Party Administrators to submit blind specimens. The final rule becomes effective Jan. 1, 2018.
“The opioid crisis is a threat to public safety when it involves safety-sensitive employees involved in the operation of any kind of vehicle or transport,” said DOT Secretary Elaine L. Chao. “The ability to test for a broader range of opioids will advance transportation safety significantly and provide another deterrence to opioid abuse, which will better protect the public and ultimately save lives.”
Click here to read more from DOT.
Click here to read the final rule as published in the Federal Register.
Related News
- Mourning the Loss of Brother Benjamin Bicknell
- I’m Not Qualified =’s I’m Not Doing It!
- Train Lengths Would Be Capped Under New Arizona Bill
- Senate Hearing Highlights the Good, the Bad, and The Ugly of RRB
- On-Duty Assault Leaves Amtrak Conductor Facing Financial Hardship
- Transit Equity Day: Remembering Rosa Parks
- Railroads Have Short Memories: East Palestine 3 Years Later
- SMART Local 1 signs new contractor to complete specialized workforce request
- RIDER Safety ACT Aims to Curb Transit Assaults Nationwide
- Rail Safety Is Too Important For Corporate Discretion